

Resource Summary Report

Generated by NIF on Sep 8, 2026

Brilliant Violet 605(TM) anti-human CD14

RRID:AB_2563798

Type: Antibody

Proper Citation

BioLegend Cat# 301834, RRID:AB_2563798

Antibody Information

URL: http://antibodyregistry.org/AB_2563798

Proper Citation: BioLegend Cat# 301834, RRID:AB_2563798

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD14

Description: This monoclonal targets CD14

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone M5E2

Antibody ID: AB_2563798

Vendor: BioLegend

Catalog Number: 301834

Alternative Catalog Numbers: 301833

Record Creation Time: 20231110T035213+0000

Record Last Update: 20260828T232315+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD14.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Walsh MJ, et al. (2026) Cellular and molecular profiling of collagenous gastritis implicates pathogenic CD4+ T cells. iScience, 29(1), 114344.

Williams WB, et al. (2024) Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. Cell, 187(12), 2919.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Caielli S, et al. (2024) Type I IFN drives unconventional IL-1 γ secretion in lupus monocytes. Immunity, 57(11), 2497.

Lock RI, et al. (2024) Macrophages enhance contractile force in iPSC-derived human engineered cardiac tissue. Cell reports, 43(6), 114302.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 185(5), 916.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell stem cell, 28(4), 623.

Li D, et al. (2021) In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 184(16), 4203.

Vora AA, et al. (2021) Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells. STAR protocols, 2(2), 100565.

Wang J, et al. (2020) Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia. Cell, 183(7), 1867.

Hagan T, et al. (2019) Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell, 178(6), 1313.

Böiers C, et al. (2018) A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1. *Developmental cell*, 44(3), 362.